Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Selectivity interaction (KinomeScan (DiscoverX)) EUB0000727a PAK2
Assay data:1 Tested
SummaryRelated BioAssays by Target
Selectivity interaction (KinomeScan (DiscoverX, competition-binding assay)) EUB0000164c PAK2
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Inhibition of recombinant human PAK2 (3 to end residues) assessed as residual activity at 1 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by radiometric scintillation counting method relative to control
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of human PAK2 assessed as residual activity at 30 uM relative to control
Inhibition of human PAK2 at 1 uM by DiscoverX KINOMEscan assay relative to control
Inhibition of full length nanoLuc-tagged human PAK2 expressed in HEK293 cells using NanoBRET NanoGlo substrate incubated for 2 hrs in presence of tracer K10 by NanoBRET assay
Inhibition of human PAK2 by radiometric PanQinase activity assay
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of human PAK2 at 1 uM by radiometric PanQinase activity assay relative to control (Rvb=50%)
PAK2 DiscoveRx kinase panel
PAK2(h) Kinase panel
Inhibition of PAK2 (unknown origin) at 1 uM
Inhibition of PAK2 (unknown origin) assessed as residual activity at 10 uM in presence of [33P]gamma-ATP by radiometric filter binding assay
Inhibition of human recombinant PAK2 assessed as reduction in substrate phosphorylation at 50 to 500 nM using ATP and Ulight-CKKSRGDYMTMQIG (IRS-1) incubated for 60 min by LANCE detection method
Mobility Shift Assay from US Patent US9365572: "PI3K and/or mTOR inhibitor"
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Z'-LYTEBiochemical Assay from Article 10.1074/jbc.M113.510933: "FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas."
Assay data:3 Active, 3 Activity ≤ 1 µM, 3 Tested
KinomeScan assay: inhibition of PAK2
Assay data:108 Tested
PAK2(h) Eurofins kinase panel
PAK2 ProQinase selectivity panel
PAK2 (PAK65) Kinase screen
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on